A new PET radiopharmaceutical based on carbon-11-labeled sarcosine (C-11 sarcosine) could offer an alternative to choline 11-based PET for imaging patients with prostate cancer, according to a study published in the Journal of Nuclear Medicine (JNM). {read more here}